Characteristics of H3 K27M-mutant gliomas in adults

被引:213
|
作者
Meyronet, David [1 ,2 ,3 ]
Esteban-Mader, Maud [4 ]
Bonnet, Charlotte [4 ]
Joly, Marie-Odile [2 ,5 ]
Uro-Coste, Emmanuelle [6 ]
Amiel-Benouaich, Alexandra [7 ]
Forest, Fabien [8 ]
Rousselot-Denis, Cecilia [9 ]
Burel-Vandenbos, Fanny [10 ]
Bourg, Veronique [11 ]
Guyotat, Jacques [12 ]
Fenouil, Tanguy [1 ]
Jouvet, Anne [1 ,2 ]
Honnorat, Jerome [2 ,4 ,13 ]
Ducray, Francois [2 ,3 ,4 ]
机构
[1] Hosp Civils Lyon, Grp Hosp Est, Serv Neuropathol, 59 Bvd Pinel, F-69394 Lyon, France
[2] Univ Claude Bernard Lyon 1, Lyon, France
[3] CNRS, Dept Canc Cell Plast, Canc Res Ctr Lyon, INSERM,U1052,UMR5286, Lyon, France
[4] Hosp Civils Lyon, Grp Hosp Est, Serv Neurooncol, Lyon, France
[5] Hosp Civils Lyon, Hop Edouard Herriot, Serv Anat & Cytol Pathol, Lyon, France
[6] CHU Toulouse, Hop Rangueil, Serv Anat & Cytol Pathol, Toulouse, France
[7] CHU Toulouse, Hop Pierre Paul Riquet, Serv Neurol, Toulouse, France
[8] CHU St Etienne, Hop Nord, Serv Anat & Cytol Pathol, St Etienne, France
[9] CHU Tours, Hop Bretonneau, Serv Anat & Cytol Pathol, Tours, France
[10] CHU Nice, Hop Pasteur, Serv Anat & Cytol Pathol, Nice, France
[11] CHU Nice, Hop Pasteur, Serv Neurol, Nice, France
[12] Hosp Civils Lyon, Grp Hosp Est, Serv Neurochirurg D, Lyon, France
[13] Univ Lyon, Inst NeuroMyoGene, INSERM 1217, CNRS 5310, Lyon, France
关键词
glioma; histone; H3; K27M; IDH; INTRINSIC PONTINE GLIOMA; TERT PROMOTER MUTATIONS; H3F3A K27M MUTATIONS; HIGH-GRADE GLIOMAS; PEDIATRIC GLIOBLASTOMA; PILOCYTIC ASTROCYTOMA; GLIONEURONAL TUMORS; DRIVER MUTATIONS; GENE-EXPRESSION; HISTONE H3.3;
D O I
10.1093/neuonc/now274
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background. Diffuse H3 K27M-mutant gliomas occur primarily in children but can also be encountered in adults. The aim of this study was to describe the characteristics of H3 K27M-mutant gliomas in adults. Methods. We analyzed the characteristics of 21 adult H3 K27M-mutant gliomas and compared them with those of 135 adult diffuse gliomas without histone H3 and without isocitrate dehydrogenase (IDH) mutation (IDH/H3 wild type). Results. The median age at diagnosis in H3 K27M-mutant gliomas was 32 years (range: 18-82 y). All tumors had a midline location (spinal cord n = 6, thalamus n = 5, brainstem n = 5, cerebellum n = 3, hypothalamus n = 1, and pineal region n = 1) and were IDH and BRAF-V600E wild type. The identification of an H3 K27M mutation significantly impacted the diagnosis in 3 patients (14%) for whom the histological aspect initially suggested a diffuse low-grade glioma and in 7 patients (33%) for whom pathological analysis hesitated between a diffuse glioma, ganglioglioma, or pilocytic astrocytoma. Compared with IDH/H3 wild-type gliomas, H3 K27M-mutant gliomas were diagnosed at an earlier age (32 vs 64 y, P < .001), always had a midline location (21/21 vs 21/130, P < .001), less frequently had a methylated MGMT promoter (1/21 vs 52/129, P = .002), and lacked EGFR amplification (0/21 vs 26/128, P = .02). The median survival was 19.6 months in H3 K27M-mutant gliomas and 17 months in IDH/H3 wild-type gliomas (P = .3). Conclusion. In adults, as in children, H3 K27M mutations define a distinct subgroup of IDH wild-type gliomas characterized by a constant midline location, low rate of MGMT promoter methylation, and poor prognosis.
引用
收藏
页码:1127 / 1134
页数:8
相关论文
共 50 条
  • [41] A validated prognostic nomogram for patients with H3 K27M-mutant diffuse midline glioma
    Youheng Peng
    Yanming Ren
    Bowen Huang
    Jun Tang
    Yan Jv
    Qing Mao
    Yanhui Liu
    Yinjie Lei
    Yuekang Zhang
    Scientific Reports, 13
  • [42] A MULTICENTER, RETROSPECTIVE ANALYSIS OF PROGNOSTIC FACTORS IN INTRACRANIAL H3 K27M-MUTANT DIFFUSE MIDLINE GLIOMA IN ADULTS
    Ryba, Alice
    Oezdemir, Zeynep
    Nissimov, Nitzan
    Hoenikl, Lisa
    Neidert, Nicolas Noel
    Jakobs, Martin
    Kalasauskas, Darius
    Krigers, Aleksandrs
    Freyschlag, Christian
    Ringel, Florian
    Trong, Philip Dao
    Heiland, Dieter Henrik
    Gempt, Jens
    Onken, Julia
    Molina, Eric Suero
    Westphal, Manfred
    Schueller, Ulrich
    Mohme, Malte
    NEURO-ONCOLOGY, 2023, 25
  • [43] Absence of MGMT promoter methylation in diffuse midline glioma, H3 K27M-mutant
    Banan, Rouzbeh
    Christians, Arne
    Bartels, Stephan
    Lehmann, Ulrich
    Hartmann, Christian
    ACTA NEUROPATHOLOGICA COMMUNICATIONS, 2017, 5
  • [44] CLINICAL EFFICACY OF ONC201 IN THALAMIC H3 K27M-MUTANT GLIOMA
    Kawakibi, Abed Rahman
    Gardner, Sharon
    Chi, Andrew
    Kurz, Sylvia
    Wen, Patrick
    Arrillaga-Romany, Isabel
    Batchelor, Tracy
    Butowski, Nicholas
    Sumrall, Ashley
    Shonka, Nicole
    Harrison, Rebecca
    DeGroot, John
    Mehta, Minesh
    Odia, Yazmin
    Hall, Matthew
    Daghistani, Doured
    Cloughesy, Timothy
    Ellingson, Benjamin
    Umemura, Yoshie
    Schwartz, Jonathan
    Yadav, Vivekanand
    Cartaxo, Rodrigo
    Miklja, Zachary
    Bruzek, Amy
    Siada, Ruby
    Mullan, Brendan
    Stallard, Stefanie
    Muruganand, Ashwath
    Wierzbicki, Kyle
    Paul, Alyssa
    Wolfe, Ian
    Kumar-Sinha, Chandan
    Marini, Bernard
    Leonard, Marcia
    Garton, Hugh
    Mody, Rajen
    Robertson, Patricia
    Merdinger, Krystal
    Tarapore, Rohinton
    Oster, Wolfgang
    Allen, Joshua
    Koschmann, Carl
    NEURO-ONCOLOGY, 2019, 21 : 186 - 186
  • [45] Single agent activity of ONC201 in non-midline H3 K27M-mutant diffuse gliomas.
    Odia, Yazmin
    Sumrall, Ashley Love
    Cloughesy, Timothy Francis
    Nghiemphu, Phioanh Leia Leia
    Hall, Matthew David
    Daghistani, Doured
    Mehta, Minesh P.
    Lassman, Andrew B.
    Arrillaga-Romany, Isabel
    Gardner, Sharon L.
    Tarapore, Rohinton
    Lu, Guangrong
    Allen, Joshua E.
    Wen, Patrick Y.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [46] CLINICAL EFFICACY OF ONC201 IN NEWLY DIAGNOSED DIPG AND IN PREVIOUSLY IRRADIATED PEDIATRIC H3 K27M-MUTANT GLIOMAS
    Gardner, Sharon
    Koschmann, Carl
    Tarapore, Rohinton S.
    Allen, Jeffrey
    Zaky, Wafik
    Odia, Yazmin
    Hall, Matthew
    Daghistani, Doured
    Khatib, Ziad
    Aguilera, Dolly
    MacDonald, Tobey
    Fouladi, Maryam
    McGovern, Susan
    Mueller, Sabine
    Kline, Cassie
    Vitanza, Nicholas
    Lu, Guangrong
    Allen, Joshua
    Khatua, Soumen
    NEURO-ONCOLOGY, 2020, 22 : 45 - 45
  • [47] ONC201 in previously -irradiated pediatric H3 K27M-mutant glioma.
    Gardner, Sharon L.
    Allen, Jeffrey C.
    Zaky, Wafik Tharwat
    Odia, Yazmin
    Daghistani, Doured
    Khatib, Ziad
    Koschmann, Carl Johannes
    Aguilera, Dolly
    MacDonald, Tobey J.
    Chi, Andrew S.
    Tarapore, Rohinton
    Merdinger, Krystal
    Oster, Wolfgang
    Allen, Joshua E.
    Khatuan, Soumen
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [48] ONC201 (Dordaviprone) in Recurrent H3 K27M-Mutant Diffuse Midline Glioma
    Arrillaga-Romany, Isabel
    Gardner, Sharon L.
    Odia, Yazmin
    Aguilera, Dolly
    Allen, Joshua E.
    Batchelor, Tracy
    Butowski, Nicholas
    Chen, Clark
    Cloughesy, Timothy
    Cluster, Andrew
    de Groot, John
    Dixit, Karan S.
    Graber, Jerome J.
    Haggiagi, Aya M.
    Harrison, Rebecca A.
    Kheradpour, Albert
    Kilburn, Lindsay B.
    Kurz, Sylvia C.
    Lu, Guangrong
    MacDonald, Tobey J.
    Mehta, Minesh
    Melemed, Allen S.
    Nghiemphu, Phioanh Leia
    Ramage, Samuel C.
    Shonka, Nicole
    Sumrall, Ashley
    Tarapore, Rohinton S.
    Taylor, Lynne
    Umemura, Yoshie
    Wen, Patrick Y.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (13) : 1542 - 1552
  • [49] Cerebellar Diffuse Midline Glioma, H3 K27M-Mutant in an Adult Patient: Case Report
    Craig, Zachary
    Malafronte, Patrick
    Johnson, Jeptha
    Theeler, Brett
    NEUROLOGY, 2017, 88
  • [50] Genomic profiling and prognostic factors of H3 K27M-mutant spinal cord diffuse glioma
    Chai, Rui-Chao
    Yan, Hao
    An, Song-Yuan
    Pang, Bo
    Chen, Hui-Yuan
    Mu, Quan-Hua
    Zhang, Ke-Nan
    Zhang, Yao-Wu
    Liu, Yu-Qing
    Liu, Xing
    Zhao, Zheng
    Jiang, Tao
    Wang, Yong-Zhi
    Jia, Wen-Qing
    BRAIN PATHOLOGY, 2023, 33 (04)